^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Gastroesophageal Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    08/14/2020
    Excerpt:
    Esophageal and Esophagogastric Junction cancer...Trastuzumab should be added to first-line chemotherapy in combination with a fluoropyrimidine and a platinum agent (category 1 in combination with cisplatin;154 category 2A in combination with other platinum agents) in patients with HER2-positive disease....
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastroesophageal Junction Adenocarcinoma)
    Excerpt:
    Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

    Excerpt:
    ...- Pathologically or cytologically confirmed metastatic or primary esophagogastric cancer HER2 positive status by FISH or IHC as currently being implemented for patients with esophagogastric cancer....
    Trial ID:
    NCT02023996
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Dig Liver Dis
    Title:

    Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study

    Published date:
    07/06/2023
    Excerpt:
    After a median follow-up of 29 months, the 18-month DFS was 80.4% (95% CI 68.9-93.8) and the 2-year OS rate was 89.0%. Subgroup analysis showed a longer DFS for gastric tumor than gastro-esophageal junction tumor...This study suggests that perioperative chemotherapy with trastuzumab in patients with HER2-positive GE-ADK is feasible and safe with encouraging survival.
    DOI:
    10.1016/j.dld.2023.06.007
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JAMA Oncol
    Title:

    FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial

    Published date:
    05/29/2020
    Excerpt:
    Trastuzumab was administered as a 6 mg/kg loading dose, followed by 4 mg/kg every 14 days in patients with ERBB2-positive disease....The ORR was 61%(95% CI, 44.5%-75.8%) (25 of 41) in the ERBB2-negative group and 85% (95% CI, 65.1%-95.6%) (22 of 26) in the ERBB2-positive group, including 1 patient with complete response.
    DOI:
    10.1001/jamaoncol.2020.2020
    Trial ID:
    NCT01928290